Limits...
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.

Knauer M, Cardoso F, Wesseling J, Bedard PL, Linn SC, Rutgers EJ, van 't Veer LJ - Br. J. Cancer (2010)

Bottom Line: However, the majority of patients does not recur and might thus be overtreated with adjuvant systemic therapy.We investigated whether the 70-gene MammaPrint signature identifies HER-2-positive patients with favourable outcome. in all, 168 T1-3, N0-1, HER-2-positive patients were identified from a pooled database, classified by the 70-gene signature as good or poor prognosis, and correlated with long-term outcome.The 70-gene signature classified 20 (22%) patients as good prognosis, with 10-year distant disease-free survival (DDFS) of 84%, compared with 69 (78%) poor prognosis patients with 10-year DDFS of 55%.

View Article: PubMed Central - PubMed

Affiliation: Division of Diagnostic Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam NL-1066CX, The Netherlands.

Show MeSH

Related in: MedlinePlus

Ten-year distant disease-free survival (left) and breast cancer-specific survival (right) according to the 70-gene signature for the 89 HER-2-positive patients who did not receive chemotherapy or trastuzumab.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3008599&req=5

fig1: Ten-year distant disease-free survival (left) and breast cancer-specific survival (right) according to the 70-gene signature for the 89 HER-2-positive patients who did not receive chemotherapy or trastuzumab.

Mentions: Detailed tumour and treatment characteristics of the HER-2-positive study population are shown in Table 1. After a median follow-up of 65 months (range 4–303), 49 (29%) distant recurrences and 41 (24%) breast cancer-specific deaths occurred in the 168 HER-2-positive patients. We focused our analyses on patients who did not receive adjuvant chemotherapy or trastuzumab to assess the prognostic value of the 70-gene signature in a more homogeneous group of HER-2-positive patients. In this group of 89 patients without adjuvant chemotherapy, 36 patients (40%) received adjuvant endocrine treatment. The 70-gene prognosis signature classified 20 (22%) patients as good prognosis, with 10-year distant DDFS of 84%, compared with 69 (78%) poor prognosis patients with 10-year DDFS of 55%. The estimated HRs were 4.5 (95% CI 1.1–18.7, P=0.04) and 3.8 (95% CI 0.9–15.8, P=0.07) for DDFS and BCSS, respectively. The corresponding Kaplan–Meier curves with log rank P-values for DDFS and BCSS are shown in Figure 1.


Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.

Knauer M, Cardoso F, Wesseling J, Bedard PL, Linn SC, Rutgers EJ, van 't Veer LJ - Br. J. Cancer (2010)

Ten-year distant disease-free survival (left) and breast cancer-specific survival (right) according to the 70-gene signature for the 89 HER-2-positive patients who did not receive chemotherapy or trastuzumab.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3008599&req=5

fig1: Ten-year distant disease-free survival (left) and breast cancer-specific survival (right) according to the 70-gene signature for the 89 HER-2-positive patients who did not receive chemotherapy or trastuzumab.
Mentions: Detailed tumour and treatment characteristics of the HER-2-positive study population are shown in Table 1. After a median follow-up of 65 months (range 4–303), 49 (29%) distant recurrences and 41 (24%) breast cancer-specific deaths occurred in the 168 HER-2-positive patients. We focused our analyses on patients who did not receive adjuvant chemotherapy or trastuzumab to assess the prognostic value of the 70-gene signature in a more homogeneous group of HER-2-positive patients. In this group of 89 patients without adjuvant chemotherapy, 36 patients (40%) received adjuvant endocrine treatment. The 70-gene prognosis signature classified 20 (22%) patients as good prognosis, with 10-year distant DDFS of 84%, compared with 69 (78%) poor prognosis patients with 10-year DDFS of 55%. The estimated HRs were 4.5 (95% CI 1.1–18.7, P=0.04) and 3.8 (95% CI 0.9–15.8, P=0.07) for DDFS and BCSS, respectively. The corresponding Kaplan–Meier curves with log rank P-values for DDFS and BCSS are shown in Figure 1.

Bottom Line: However, the majority of patients does not recur and might thus be overtreated with adjuvant systemic therapy.We investigated whether the 70-gene MammaPrint signature identifies HER-2-positive patients with favourable outcome. in all, 168 T1-3, N0-1, HER-2-positive patients were identified from a pooled database, classified by the 70-gene signature as good or poor prognosis, and correlated with long-term outcome.The 70-gene signature classified 20 (22%) patients as good prognosis, with 10-year distant disease-free survival (DDFS) of 84%, compared with 69 (78%) poor prognosis patients with 10-year DDFS of 55%.

View Article: PubMed Central - PubMed

Affiliation: Division of Diagnostic Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam NL-1066CX, The Netherlands.

Show MeSH
Related in: MedlinePlus